Verona Pharma plc Sponsored ADR Aktie News

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verona Pharma plc (NasdaqGM: VRNA) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Verona will receive $107.00 in cash for each share of American Depositor...

Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verona Pharma plc (NASDAQ: VRNA) to Merck for $107.00 per American Depository Share is fair to Verona shareholders. Halper Sadeh encourages Verona shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 o...

Verona Pharma Plc (NASDAQ: VRNA) rallied about 20% on Wednesday after Merck & Co Inc (NYSE: MRK) said it will buy the UK-based biotech firm known for its COPD drug Ohtuvayre. The $10 billion all-cash agreement values VRNA shares at $107 each, representing about a 23% premium on their previous close.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck said Wednesday it would buy COPD drugmaker Verona Pharma for $10 billion. The news sent Verona stock flying.

Merck announced Wednesday it will acquire UK-based Verona Pharma for approximately $10 billion, deepening its commitment to respiratory treatments as the company prepares for a revenue gap following the patent expiry of its cancer blockbuster, Keytruda. This marks Merck's largest transaction since its $10.

Verona Pharma's stock soars toward a record after $10 billion buyout deal with Merck.